Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Kansas: - University of Kansas Cancer Center — Kansas City, Kansas
- Lawrence Memorial Hospital — Lawrence, Kansas
- The University of Kansas Cancer Center - Olathe — Olathe, Kansas
- University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
- Salina Regional Health Center — Salina, Kansas
Phase 2, Phase 3 Recruiting Industry
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…
Sponsor: Pfizer
NCT ID: NCT06989437
Sites in Kansas: - United Imaging Consultants — Lenexa, Kansas
- MidAmerica Cancer Care- American Oncology Partners — Merriam, Kansas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Sponsor: Immuneering Corporation
NCT ID: NCT07562152
Sites in Kansas: - University of Kansas Cancer Center — Fairway, Kansas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07252232
Sites in Kansas: - University of Kansas Medical Center Research Institute, Inc. — Lawrence, Kansas
Phase 2 Recruiting NIH
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in Kansas: - University of Kansas Clinical Research Center — Fairway, Kansas
- Central Care Cancer Center - Garden City — Garden City, Kansas
- Central Care Cancer Center - Great Bend — Great Bend, Kansas
- HaysMed — Hays, Kansas
- University of Kansas Cancer Center — Kansas City, Kansas
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nod…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04172532
Sites in Kansas: - University of Kansas Clinical Research Center — Fairway, Kansas
- HaysMed — Hays, Kansas
- University of Kansas Cancer Center — Kansas City, Kansas
- Lawrence Memorial Hospital — Lawrence, Kansas
- The University of Kansas Cancer Center - Olathe — Olathe, Kansas
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Kansas: - The University of Kansas Clinical Research Center — Westwood, Kansas
Phase 2 Recruiting Industry
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newl…
Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in Kansas: - Cancer Centers of Kansas — Wichita, Kansas
Phase 1, Phase 2 Recruiting Industry
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Kansas: - University of Kansas — Kansas City, Kansas
Phase 1 Recruiting Industry
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
Sponsor: AstraZeneca
NCT ID: NCT06218914
Sites in Kansas: - Research Site — Westwood, Kansas
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Kansas: - Central Care Cancer Center - Garden City — Garden City, Kansas
- Central Care Cancer Center - Great Bend — Great Bend, Kansas
- Veteran Administration Eastern Kansas Healthcare — Leavenworth, Kansas
- Mercy Hospital Pittsburg — Pittsburg, Kansas
- Cotton O'Neil Cancer Center / Stormont Vail Health — Topeka, Kansas
Recruiting Industry
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected …
Sponsor: Paradigm Health
NCT ID: NCT06605404
Sites in Kansas: - Cotton O'Neil Cancer Center [Stormont Vail] — Topeka, Kansas
- Cancer Center of Kansas — Wichita, Kansas
Recruiting Academic/Other
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individ…
Sponsor: Arbor Research Collaborative for Health
NCT ID: NCT04970056
Sites in Kansas: - University of Kansas Medical Center — Kansas City, Kansas
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Kansas: - Saint Luke's Cancer Instititute - South — Overland Park, Kansas
Recruiting Industry
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…
Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Kansas: - Research Site — Topeka, Kansas